|drug4795||urinary NGAL, TIMP-2, IGFBP7, IL-6, viral load and metabolomic Wiki||1.00|
|D045169||Severe Acute Respiratory Syndrome NIH||0.04|
There is one clinical trial.
The purpose of this study is to identify healthcare workers with SARS CoV 2 antibodies who have not been previously diagnosed and are presumed COVID-19 negative, then determine the level of immunity in this population which could inform further decisions about widespread antibody testing in a healthcare worker population.
Description: Presence of IgG antibodies detectedMeasure: Prevalence of COVID19 Antibody Positivity Time: 1 month
Description: Survey of participants to gauge their confidence they will be antibody positiveMeasure: Ability to predict immune status/antibody positivity Time: 1 month
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports